|ITEM METADATA RECORD
|Title: ||Early Serum Infliximab Trough Level, Clinical Disease Activity and CRP as Markers of Sustained Benefit of Infliximab Treatment in Crohn's Disease: A Post-hoc Analysis of the ACCENT1 Trial|
|Authors: ||Cornillie, F|
Rutgeerts, Paul #
|Issue Date: ||Oct-2011 |
|Publisher: ||Nature Publishing Group|
|Host Document: ||American Journal of Gastroenterology vol:106 pages:S462-S463|
|Conference: ||- edition:- location:- date:-|
|Publication status: ||published|
|KU Leuven publication type: ||IMa|
|Appears in Collections:||Translational Research in GastroIntestinal Disorders |
|Files in This Item:
There are no files associated with this item.
All items in Lirias are protected by copyright, with all rights reserved.